NCT00001903 is a Phase 4 clinical trial of RSV Polyclonal Immunoglobulin in Respiratory Syncytial Virus Infection, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Who is sponsoring NCT00001903?

NCT00001903 is sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

What drugs are being tested in NCT00001903?

Interventions in NCT00001903: RSV Polyclonal Immunoglobulin.

What condition does NCT00001903 study?

NCT00001903 studies Respiratory Syncytial Virus Infection.

Is NCT00001903 still recruiting?

NCT00001903 is currently completed. Last updated 3 March 2008.

Last reviewed 2008-03-03 · How we verify

NCT00001903

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prevention of RSV Infections in Bone Marrow Transplant Recipients

Completed Phase 4 Last updated 3 March 2008

What this trial tests

Phase 4 trial testing RSV Polyclonal Immunoglobulin in Respiratory Syncytial Virus Infection in 120 participants. Completed in 1 May 2001.

Timeline

1 April 1999

1 May 2001

Quick facts

Lead sponsor	National Institute of Allergy and Infectious Diseases (NIAID)
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Primary purpose	treatment
Enrollment	120
Start date	1 April 1999
Estimated completion	1 May 2001
Sites	1 location across United States

Drugs / interventions tested

RSV Polyclonal Immunoglobulin — full drug profile →

Conditions studied

Respiratory Syncytial Virus Infection — all drugs for Respiratory Syncytial Virus Infection →

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Who can join

Eligibility, any sex, with Respiratory Syncytial Virus Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Respiratory Syncytial Virus (RSV) infections are very common and widespread. By age 5, virtually everyone has been infected and developed antibodies against some strain of the virus. RSV infections happen during adulthood, leading to common cold syndromes. In Bone Marrow Transplant recipients the disease is much more severe, usually progressing to pneumonia. This phenomenon is associated with mortality rates around 60-80%. RSV Polyclonal Immunoglobulin (Respigam® (Registered Trademark)) has been approved by the Food and Drug Administration and recommended by the American Academy of Pediatrics for prophylaxis of RSV disease in premature babies and children born with bronchopulmonary dysplasia. Furthermore, it has been used to treat RSV pneumonia in children and Bone Marrow Transplant recipients with encouraging results and no complications. Currently, no preventive strategies are available when approaching this infection among bone marrow transplant patients. We intend to prevent our bone marrow transplant patients from developing RSV pneumonia by employing the strategy already used in premature babies, i.e., by passive immunization with Respigam® (Registered Trademark). Our goal to evaluate the efficacy and safety of this strategy in such immunocompromised population. We believe that this will be a more reasonable approach than waiting for the infection to settle in and only then treating it, because optimal therapy is not currently available.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Respiratory Syncytial Virus Infection

Currently open trials in the same condition.

NCT07402512 — A Phase III Study of Deuremidevir Hydrobromide for the Treatment of RSV Infection in Infants and Young Children · Phase 3 · recruiting
NCT06817889 — Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals · Phase 2 · recruiting
NCT07239583 — Genotype and Disease Burden of RSV in Older Vietnamese Adults (RSV: Respiratory Syncytial Virus ) · recruiting
NCT06546800 — SPECIAL INVESTIGATION FOR ABRYSVO IN INDIVIDUALS AGED 60 YEARS OR OLDER · active not recruiting
NCT06604767 — Study of a Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adults Aged · Phase 1 · active not recruiting

Other National Institute of Allergy and Infectious Diseases (NIAID) trials

Trials by the same sponsor.

NCT07216794 — Small Trial of Alendronate Impact on the Reservoir of HIV · Phase 2 · not yet recruiting
NCT07215858 — BPL-1357 Against H1N1 Influenza Virus Challenge · Phase 2 · recruiting
NCT06987318 — A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) · Phase 1 · not yet recruiting
NCT07124559 — A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of · Phase 1, PHASE2 · not yet recruiting
NCT07342491 — Dasatinib for HIV-1 Reservoir Reduction · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00001903 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Institute of Allergy and Infectious Diseases (NIAID)
Last refreshed: 3 March 2008

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00001903.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing